Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether gut dysbiosis correlates with clinical progression of Parkinson's disease (PD) over a two-year period. Researchers tracked changes in gut microbiota composition alongside demographic and clinical features across that follow-up window. The work builds on a prior report from the same group describing gut dysbiosis in PD patients. The aim was to link baseline microbial counts to later changes in motor and non-motor symptom severity.
Who was studied?
The cohort consisted of 36 patients with Parkinson's disease who were followed for two years. Patients were later divided evenly into a deteriorated group and a stable group based on how much their total UPDRS scores worsened over that period. The abstract does not provide further demographic details such as age, sex distribution, or disease duration at enrollment.
What were the most important findings?
Change in total UPDRS score over two years was predicted by baseline counts of Bifidobacterium and the Atopobium cluster, with a correlation coefficient of 0.52. Low baseline counts of Bifidobacterium and Bacteroides fragilis were associated with worsening of UPDRS I scores over two years. Low baseline Bifidobacterium was specifically linked to worsening hallucinations and delusions, while low baseline B. fragilis was linked to worsening motivation and initiative. The deteriorated group had lower baseline counts of Bifidobacterium, B. fragilis, and Clostridium leptum than the stable group at year zero, though not at year two, suggesting an accelerated decline in these bacteria preceded clinical worsening.
What are the greatest implications of this study?
These findings suggest that baseline levels of specific gut bacteria, including Bifidobacterium and Bacteroides fragilis, may serve as early indicators of which PD patients are likely to experience faster clinical deterioration. The distinct associations between particular taxa and specific symptom domains (psychiatric versus motivational) point toward possible microbiota-linked pathways influencing different aspects of PD progression. This raises the possibility that monitoring or modulating these bacterial populations could eventually inform prognostic assessment or intervention strategies in PD, though the abstract does not describe any mechanistic or interventional testing.